	US 12,226,385 B2
	Synergistic composition for activating intracellular secondary messenger(cAMP) pathway
Rajaram Samant, Thane (IN); Rajendra Prasad Tongra, Jaipur (IN); and Jotiram Palkar, Thane (IN)
Assigned to CELAGENEX RESEARCH (INDIA) PRIVATE LTD., Thane (IN)
Filed by CELAGENEX RESEARCH (INDIA) PRIVATE LTD., Maharashtra (IN)
Filed on Jun. 14, 2022, as Appl. No. 17/840,532.
Claims priority of application No. 202121051996 (IN), filed on Nov. 12, 2021.
Prior Publication US 2022/0313638 A1, Oct. 6, 2022
Int. Cl. A61K 31/197 (2006.01); A61K 9/48 (2006.01); A61K 31/155 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/197 (2013.01) [A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 31/155 (2013.01); A61P 25/28 (2018.01)]

2 Claims

1. A method of treating depression, the method comprising:

administering a unit dose of a bioactive composition twice daily to male and female subjects aged in a range of 18 to 65 years for a period of 12 weeks; and thereby

wherein the unit dose of the bioactive composition comprises:

a therapeutically active exogenous combination consisting of (3R)-3-acetyloxy-4-(trimethylazaniumyl) butanoate and N-(4-aminobutyl) guanidine or a salt thereof, wherein the (3R)-3-acetyloxy-4-(trimethylazaniumyl) butanoate is present in an amount of 500 mg and the N-(4-aminobutyl) guanidine or the salt thereof is present in an amount of 250 mg; and

pharmaceutically acceptable excipients.